How does peptide therapy work?

Peptide therapy is the physician-supervised use of short chains of amino acids to produce specific, targeted effects in the body. The peptides used in clinical practice are not the same as proteins (longer chains) and not the same as steroids (an entirely different class of molecule). They are short — usually between 3 and 50 amino acids long — and that shortness is what gives them their selectivity.

This guide explains the science from the ground up: what a peptide is, how it binds a receptor, the major categories of therapeutic peptides, what the evidence shows for each, and how a physician-led clinic in Las Vegas actually evaluates and prescribes them. It is the page I wish existed when I started integrating peptide therapy into a neurology-informed longevity practice.

— Dr. Charles Kamen, MD, board-certified neurologist (ABPN)

What is a peptide?

A peptide is a short chain of amino acids linked by the same peptide bonds that link amino acids in proteins. The distinction from a protein is length: peptides are short (typically under 50 amino acids), proteins are long. The distinction from a steroid is chemistry: peptides are made of amino acids (the same building blocks as muscle, enzymes, and most of your body), steroids are derivatives of cholesterol.

Shortness gives peptides two clinically important properties:

1. Receptor selectivity. A short peptide fits one receptor (or a small family of related receptors) rather than the broad diffuse binding that longer proteins can do. That is why a GHRH analog prompts growth hormone release without triggering unrelated pathways, and why a GLP-1 agonist reduces appetite without affecting, say, immune function.
2. Manufacturability. Short peptides can be synthesized chemically with high purity, which is what allows licensed 503A and 503B compounding pharmacies to produce them under controlled conditions with third-party testing.

How peptides produce effects in the body

Every peptide used in clinical practice works by the same basic mechanism: it binds to a specific receptor on the surface of a cell, and that binding triggers a signal inside the cell that changes the cell\'s behavior.

The signal inside the cell is usually one of two kinds:

• G-protein-coupled receptor (GPCR) signaling — the largest class of drug targets in modern medicine. GLP-1 agonists, melanocortin agonists, and most neuropeptide drugs work through GPCRs. The result is usually a fast change in cell behavior: insulin release, appetite suppression, vasodilation, etc.
• Receptor tyrosine kinase or kinase cascade signaling — common in growth-factor and regenerative peptides. The result is usually a slower change in cell behavior: gene expression, protein synthesis, cell proliferation.

The key insight is that the effect of a peptide is determined entirely by which receptor it binds. The same fundamental mechanism produces:

• Insulin release (GLP-1 agonists bind GLP-1 receptors on pancreatic beta cells)
• Growth hormone release (GHRH analogs bind GHRH receptors on pituitary somatotrophs)
• Appetite suppression (GLP-1 agonists bind GLP-1 receptors in the hypothalamus)
• Libido response (melanocortin agonists bind MC3R/MC4R in the hypothalamus)
• Tissue repair signaling (BPC-157 acts on the nitric oxide system and VEGFR2)

The major categories of therapeutic peptides

Peptides used in clinical practice fall into roughly ten mechanistic categories. Understanding the categories is more useful than memorizing individual compounds, because compounds change but mechanisms persist.

Incretin mimetics (GLP-1 and dual / triple agonists)

Bind GLP-1 receptors (and in some compounds, GIP and glucagon receptors) to increase insulin release, decrease glucagon, slow gastric emptying, and reduce appetite. This is the class that includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, dulaglutide, and exenatide — all FDA-approved. Investigational compounds in this class include retatrutide (a triple agonist) and survodutide.

GHRH analogs (growth hormone-releasing hormone)

Mimic endogenous GHRH to prompt the pituitary to release more of your own growth hormone. This is the class of sermorelin (FDA-approved as Egrifta for HIV-related lipodystrophy, used off-label and compounded for age-related GH decline), CJC-1295, and tesamorelin (FDA-approved). GHRH analogs preserve the natural pulsatile release pattern of growth hormone, which is theoretically distinct from continuous exogenous GH.

Growth hormone secretagogues / GHRPs

Mimic ghrelin (the "hunger hormone") at the GHS-R1a receptor to stimulate GH release through a different pathway than GHRH. Includes ipamorelin, GHRP-2, GHRP-6, and hexarelin. Often combined with a GHRH analog in a "blend" because the effect on GH release is additive. MK-677 (ibutamoren) is a non-peptide ghrelin mimetic grouped with this class by mechanism.

Tissue-repair peptides

BPC-157 (a fragment of body protection compound) and TB-500 (a thymosin β-4 fragment) are studied for tendon, ligament, joint, and gut healing. The evidence is largely animal and preclinical; human trial data is still limited. These are investigational in the US — not FDA-approved as finished drugs — and their FDA 503A compounding status has changed in 2026. A physician can explain the current legal status for your specific case.

Melanocortin peptides

Bind melanocortin receptors (MC1R, MC3R, MC4R, MC5R) to produce effects on sexual arousal, skin pigmentation, appetite, and inflammation. PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is also used off-label in men. Melanotan II is a related investigational compound with similar mechanism but a different risk profile.

Mitochondrial and longevity peptides

MOTS-c is a mitochondrial-derived peptide studied for metabolic effects. Epithalon (a pineal tetrapeptide) is studied for telomere and circadian effects. Human evidence is preliminary for both. A physician can explain what is currently evidence-supported versus what is still investigational.

Nootropic and CNS peptides

Semax and Selank (both heptapeptides developed at the Institute of Molecular Genetics in Russia) are studied for cognitive and anxiolytic effects. Cerebrolysin is a porcine brain-derived peptide mixture used in some countries for stroke recovery and dementia. None are FDA-approved for cognitive indications. See our neurologist\'s view on cognitive peptides for a more detailed breakdown.

Thymic and immune peptides

Thymosin alpha-1 (TA1) is FDA-approved for chronic hepatitis B and is used off-label and compounded for immune modulation. Thymosin β-4 (the parent compound of TB-500) is a naturally occurring regenerative peptide.

How a physician-led clinic decides whether to prescribe

The mechanism is one thing. The decision to prescribe is another. A physician-led clinic — as opposed to a med-spa or telehealth shop — evaluates the patient first, prescribes only what is medically appropriate, and monitors with labs.

At our Las Vegas clinic, the evaluation has five components:

1. Clinical consultation. A direct conversation with the physician about your history, current medications, prior labs, and goals. This is the part a med-spa or online vendor skips.
2. Lab review. A comprehensive panel (metabolic, hormonal, inflammatory, kidney, liver) to understand your baseline and identify anything that should be addressed before adding a peptide.
3. Honest recommendation. A clear answer on whether peptide therapy is appropriate for you — and what the expected benefit is, with realistic timelines. Some patients are told "not right for you," and that is a real, honest answer from a physician.
4. Sourcing. All peptides come from licensed U.S. 503A or 503B compounding pharmacies with third-party purity and potency testing. No "research use only" sourcing. No gray-market online vendors.
5. Monitoring. Follow-up visits and repeat labs to verify the protocol is working and to adjust or discontinue based on results.

The initial medical evaluation is $88 and is applied toward your protocol if you continue care. See our peptide therapy cost page for what that includes and how protocol pricing is structured.

Sourcing: why the pharmacy matters

The same peptide molecule, sourced from a licensed pharmacy versus an unregulated online vendor, has a meaningfully different risk profile. The peptide itself may be the same, but the surrounding process is not.

Licensed 503A or 503B pharmacy: state or FDA oversight, sterile compounding standards, third-party purity and potency testing, valid prescription required, documentation of every batch. See our 503A vs 503B comparison for the full distinction.

Unregulated "research use only" vendor: no oversight, no sterility guarantees, no verification that what is in the vial is what the label says, no way to know what solvents, impurities, or contaminants are present. The "research use only" label is a warning, not a loophole.

A physician-led clinic names the pharmacy it works with. An online vendor usually does not. The question "where does the peptide come from" is the single most useful question you can ask any clinic.

What the evidence actually shows

Honest framing of the evidence, because patients deserve it:

Of the peptides most often discussed in clinical practice, only a handful are FDA-approved with multiple Phase 3 human trials: semaglutide, tirzepatide, liraglutide, tesamorelin, and bremelanotide. For these compounds, the evidence base is solid.

For sermorelin, CJC-1295/ipamorelin, and other GHRH analogs and GHRPs, the evidence is moderate — physiological effects on GH release are well-documented, but the evidence that this translates to specific clinical outcomes in healthy adults is more limited. Patients who use these peptides often report sleep and recovery improvements; whether those reports are reliable or placebo-controlled is harder to know.

For BPC-157, TB-500, MOTS-c, epithalon, and several other compounds, the evidence is preliminary — strong animal and preclinical data, limited or no Phase 3 human data. These are investigational. A physician can use them off-label and compounded, but the evidence does not yet support the "anti-aging" or "longevity" claims that marketing sometimes attaches to them.

For the full evidence breakdown by peptide, see our peptide evidence-grade index (A-D grades on the strength of human evidence).

Safety considerations

Peptide therapy is generally well-tolerated when physician-supervised. Common considerations:

• Injection-site reactions — redness, itching, bruising at the subcutaneous injection site. Usually mild and self-limiting.
• Water retention — common with GHRH and GHRP analogs, usually mild, sometimes signals dose adjustment is needed.
• GLP-1 side effects — nausea, GI upset, reduced appetite. Often dose-related and manageable with titration.
• Hormonal interactions — peptides that affect GH or sex hormones can interact with other hormone therapies. Physician supervision is essential when combining.
• Unsupervised use risk — most safety problems in the popular discourse come from unsupervised online sourcing, not from physician-led use.

See our is peptide therapy safe? page for a more detailed safety review.